检索历史清除

首页> Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research> NINTEDANIB PLUS DOCETAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC): A NETWORK META-ANALYSIS VS. NEW THERAPEUTIC OPTIONS

NINTEDANIB PLUS DOCETAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC): A NETWORK META-ANALYSIS VS. NEW THERAPEUTIC OPTIONS

导出原文传递

翻译打印收藏纠错

作者： Popat, S. ^[1] ; Mellemgaard, A. ^[2] ; Reck, M. ^[3] ; Hastedt, C. ^[4] ; Griebsch, I

作者单位： Royal Marsden Hosp, London, England ^[1] Herlev Hosp, Herlev, Denmark ^[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany ^[3] LungenClin Grosshansdorf, Grosshansdorf, Germany ^[4]

发布时间 2020-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交